Other

Bayer Corporation

Bayer Healthcare LLC

Molecular Diagnostics, Inc.

Bayer Aktiengesellschaft

Miles Inc.

Bayer Corporation (formerly Molecular Diagnostics, Inc.)

James J Elting

Thomas R Barnett

W E Mikhail

Michael E Kamarck

Axel W Kretschmer

Jacques P Dumas

William Johnston Scott

Robin S Ling

Holia Hatoum-Makdad

Stefan Wohlfeil

Martin Beuck

Dirk Denzer

Christoph Gerdes

Siegfried Zaiss

Stefan Lohmer

Ozkan Yalkinoglu

Anke Domdey-Bette

Tom J Slooff

Graham A Gie

Ulrich E Muller

Matthias Muller-Gliemann

Rudi Grutzmann

Matthias M uller-Gliemann

William Jeffrey Allard

Ulrich E M Uller

Heinz Kolbl

John Hart

Michael Kamarck

Thomas Barnett

Jacques J Vanderlinden

Rudi Gr Utzmann

Vincent N Toscano

This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Aryl ureas with angiogenisis inhibiting activity

Aryl ureas with angiogenesis inhibiting activity

A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

cDNAs coding for members of the carcinoembryonic antigen family

Antibody preparations specifically binding to unique determinants of CEA

The phenylcyclohexylcarboxamides, some of which are known, are suitable as active compounds in medicaments, in particular in medicaments for the treatment of restenosis.

Use of phenylcyclohexylcarboxamides

The surgical garment of the present invention is to be worn by a patient. The garment is preferably a three-piece garment and is comprised preferably of polypropylene fabric. The garment pieces are a hood piece to cover a patient's head and neck, a top piece to cover a patient's torso and upper extremities and bottom pieces to cover a patient's lower extremities. The garment assists a patient in maintaining homeostasis or a constant body temperature before, during and after surgery. There is at least one opening within the garment to allow access to a patient for surgical procedures, placement of an intravenous tube into the patient, placement of a monitor sensor upon the patient, administration of a shot to the patient and other necessary medical procedures.

Surgical garment for a patient

A nucleic acid comprising a base sequence which codes for a CEA peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or infected with such cloning vehicles, polypeptides expressed by such cells, antibody preparations specific for such polypeptides, immunoassays for detecting CEA using such antibody preparations and nucleic acid hybridization methods for detecting a CEA nucleic acid sequence using a nucleic acid probe comprising the above described nucleic acid.

CDNA coding for carcinoembryonic antigen

Substituted indole derivatives are prepared by reacting appropriate carboxylic acids, if appropriate in the presence of auxiliaries, with appropriate amines. The substituted indole derivatives are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and restenosis.

Substituted indole derivatives

A method for aiding in the diagnosis of, and monitoring the progression of, breast cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g. serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of breast cancer in the patient. The progression of breast cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

Monitoring of NC 50/90 in blood samples of breast cancer patients

A nucleic acid encoding a carcinoembryonic antigen (CEA) that cross-reacts with human CEA is described. In addition, vectors and host cells containing such nucleic acids are disclosed.

An apparatus for performing hip prosthesis revision surgery includes means for preparation of the cavity left after removal of the original prosthesis. A tamp having a longitudinal passageway extending longitudinally through the stem portion thereof and a guidewire positioned in the cavity function to compact bone graft material in the cavity and form a precisely contoured new hip prosthesis receiving cavity.

System for performing hip prosthesis revision surgery

A tapered, collarless femoral hip joint prosthesis formed of Co-Cr-Mo alloy with highly polished surfaces is provided.

Femoral stem prosthesis

Growing community of inventors

Madison, CT, United States of America

James J Elting